ESLA

Business Context and Reporting Period

Estrella Immunopharma, Inc. (ESLA) is a clinical-stage biopharmaceutical company developing T-cell therapies (EB103 and EB104) for blood cancers and solid tumors. The company operates as a single segment and is classified as an emerging growth company and smaller reporting company. This Form 10-Q covers the quarterly and nine-month periods ended September 30, 2025. The company changed its fiscal year-end from June 30 to December 31 effective November 25, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased to $4.8 million for the three months ended September 30, 2025, from $3.4 million in the same period in 2024. For the nine months, expenses rose to $12.4 million from $7.8 million. The increase is primarily driven by higher research and development (R&D) costs related to the STARLIGHT-1 clinical trial, specifically patient dosing milestones and site activation fees paid to related party Eureka Therapeutics.
• Related Party Liabilities: Accrued liabilities to related parties surged to $12.9 million as of September 30, 2025, compared to $2.8 million at December 31, 2024. This reflects the accrual of milestone payments for nine patients dosed and the activation of a second clinical trial site.
• Derivative Liabilities: A new derivative liability of $385,355 was recorded related to "True-Up Shares" features in recent securities purchase agreements. This resulted in a $67,039 loss from changes in fair value for the nine-month period.
• Financing Activity: The company raised approximately $2.4 million in gross proceeds through private placements (PIPE) between May and September 2025, issuing 1.6 million shares. This contrasts with the prior year period which saw no such equity raises.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management states that while the company has a working capital deficit of approximately $11.3 million, it believes it has sufficient funds and the ability to raise additional capital through its $50 million equity line with White Lion to meet obligations for the next 12 months. However, the company expects to continue incurring losses until regulatory approval and commercialization are achieved.
• Clinical Progress: The Phase I/II STARLIGHT-1 trial for EB103 is ongoing. As of September 30, 2025, nine patients had been dosed, and a second clinical site was activated. In November 2025 (subsequent event), the company announced the completion of Phase I dosing.
• Internal Controls: Management identified a material weakness in internal control over financial reporting due to a lack of qualified full-time personnel with appropriate accounting knowledge. While remediation efforts (hiring, process implementation) began in 2024, controls were deemed ineffective as of September 30, 2025.
• Risks: Key risks include the failure to secure additional financing, the inability to replace Eureka Therapeutics if the services agreement is terminated, and the high volatility of the stock price affecting the valuation of derivative liabilities and warrant exercise potential (warrants are currently out of the money with a $11.50 strike price).

Investor Verification Checklist

• Related Party Dependence: Verify the terms and termination clauses of the Statement of Work with Eureka Therapeutics, which controls the manufacturing and clinical trial execution, representing a significant portion of liabilities and expenses.
• Cash Runway: Assess the sufficiency of the $1.6 million cash balance against the $12.9 million accrued liability to Eureka and ongoing burn rate to confirm the 12-month liquidity assertion.
• Derivative Liability Valuation: Review the assumptions (volatility, risk-free rate) used in the Monte Carlo simulation for the $385,355 derivative liability, as changes in stock price will directly impact future earnings.
• Equity Line Availability: Confirm the status of the $50 million equity line with White Lion, specifically whether the 20% issuance cap requires shareholder approval for future draws.
• Internal Control Remediation: Monitor progress on hiring qualified accounting personnel to address the material weakness in financial reporting controls.